Pathophysiology of Placenta Accreta Clinical Trial
Official title:
Impact of Netrin-1 in the Pathophysiology of Placenta Accreta Spectrum
| Verified date | May 2024 |
| Source | Assiut University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
The main goal of this study the possible involvement of netrin-1 into the pathophysiology of placenta accrete spectrum. To delineate the role of netrin-1, neogenin - zeb1 signaling pathway in mechanism of morbidly adherent placenta.
| Status | Completed |
| Enrollment | 60 |
| Est. completion date | December 1, 2023 |
| Est. primary completion date | November 1, 2022 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Female |
| Age group | 20 Years to 40 Years |
| Eligibility | Inclusion Criteria: - ages between 20 to 40 years will be included. - Gestational age: between 34 to 38 weeks. - History of previous cesarean sections. suspected intra-operative abnormal placental adhesion of variable degrees Exclusion Criteria: Fundal and middle anterior or posterior placenta. • Pregnancy associated with morbid conditions as: hypertension, diabetes mellitus, autoimmune disease, cardiac disease, renal disease, and endocrinal disease. |
| Country | Name | City | State |
|---|---|---|---|
| Egypt | Hanaa Mohammed Mohammed Sayed | Assiut |
| Lead Sponsor | Collaborator |
|---|---|
| Assiut University |
Egypt,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | impact of netrin-1 in the pathophysiology of placenta accreta spectrum | Estimation of local placental netrin-1 protein expression by immunohistochemistry , Estimation of local placental expression of neognin by immunohistochemistry. Estimation of local placental expression of Zeb-1 by immunohistochemistry | baseline |